Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fed Conditions
Primary Purpose
Healthy
Status
Completed
Phase
Phase 1
Locations
India
Study Type
Interventional
Intervention
Rabeprazole sodium 20 mg Delayed Release tablet
Sponsored by
About this trial
This is an interventional trial for Healthy
Eligibility Criteria
Inclusion Criteria:
- Healthy male human volunteers within the age range of 18 to 50 years
- A body mass index within 18-25 Kg/m2
- Given written informed consent to participate in the study
- Absence Of disease markers of HIV 1& 2, hepatitis B & C virus and RPR.
- Absence of significant disease or clinically' significant abnormal laboratory values on laboratory evaluation, medical history and medical examination during the screening
- A normal 12 lead ECG.
- A normal chest X-ray (FA view)
- Comprehension of the nature and purpose'of the study and compliance with the requirement of the entire protocol
- No history or no evidence of hypersensitivity to rabeprazole substituted benzimidazoles or to any component of the formulation
- No history of Anaphylaxis arid Angioedema
- No history or presence of gastric malignancy
- No history of significant systemic diseases
- No history of psychiatric disorders
- No history of addiction to any recreational drug or drug dependence
- No donation of blood(one unit or 350 mL) within 90 days prior to study check-in
- No participation in any clinical study within the last 90 days
- No receipt of any prescription drugs or over-the-counter drugs (e.g.: Cold preparations, and antacid preparations' vitamins and natural products used for therapeutic benefits), within two weeks prior to study check-in
- No history of dehydration from diarrhea, vomiting or any other reason within a period of 24.0 hours prior to study check-in
- No family history of neurological disorders
- Not consumed alcohol and xanthin containing food and beverages, (chocolates, tea,coffee or cola drinks) cigarettes and tobacco products for at least 48.0 hours prior to study check-in for each period.
- Negative results for drugs of abuse (Benzodiazepines, Cocaines, Opioids, Amphetamines, Cannabinoids and Barbiturates) in urine during the day of study check-in of each period
- Not consumed grapefruit(mosumbi/sweet lime) juice within the 48.0 hours prior to study check-in
- Negative alcohol breath analysis during the study check-in of each period
Exclusion Criteria:
- History of seizures
- Received pharmacological agents known to significantly induce or inhibit drug metabolizing enzymes within 14 days of the start of the study
- History of alcohol consumption for more than two units/day (1 unit=30 mL of spirit/or 1 pint of beer), or having consumed alcohol within 48.0 hours prior to check-in
- High caffeine (more than 5 cups of coffee or tea/day) or tobacco (mote than 9 cigarettes/beedies/cigars per day) consumption
- History of difficulty with donating blood or difficulty in accessibility of veins
- An unusual or abnormal diet for whatever reason e.g. because of fasting due to religious reasons
Sites / Locations
- AXIS Clinicals Limited
Outcomes
Primary Outcome Measures
bioequivalence based on Composite of Pharmacokinetics
bioequivalence; 90% geometric confidence interval of the ratio of least-squares means of the test to reference product should be within 80.00% - 125.00% for AUC-unf, AUCo-t and Cmax.
Secondary Outcome Measures
Full Information
NCT ID
NCT01990586
First Posted
November 15, 2013
Last Updated
November 15, 2013
Sponsor
Torrent Pharmaceuticals Limited
1. Study Identification
Unique Protocol Identification Number
NCT01990586
Brief Title
Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fed Conditions
Official Title
An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Rabeprazole Sodium Delayed Release Tablets 20 mg (Test, Torrent Pharmaceuticals Limited., India) Versus Aciphex® (Rabeprazole Sodium) Delayed Release Tablets 20 mg (Reference, Eisai Inc., USA) in Healthy Human Volunteers Under Fed Condition.
Study Type
Interventional
2. Study Status
Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
September 2010 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Torrent Pharmaceuticals Limited
4. Oversight
5. Study Description
Brief Summary
Objective:
Primary objective of the present study was to compare the single dose bioavailability of Torrent's Rabeprazole Sodium Delayed Release Tablets 20 mg and Aciphex® Delayed Release Tablets 20 mg (Reference, Eisai Inc., USA). Dosing periods were separated by a washout period during fed study.
Study Design:
Open-Label, Randomised, two Period, two treatment, Crossover, Single-Dose Bioequivalence Study
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy
7. Study Design
Study Phase
Phase 1
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Rabeprazole sodium 20 mg Delayed Release tablet
Primary Outcome Measure Information:
Title
bioequivalence based on Composite of Pharmacokinetics
Description
bioequivalence; 90% geometric confidence interval of the ratio of least-squares means of the test to reference product should be within 80.00% - 125.00% for AUC-unf, AUCo-t and Cmax.
Time Frame
plasma samples were obtained from blood drawn at Pre-dose and 0.5, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 8.00, 10.00, 12.00, 14.00, 18.00 and 24.00 hours after dose administration
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy male human volunteers within the age range of 18 to 50 years
A body mass index within 18-25 Kg/m2
Given written informed consent to participate in the study
Absence Of disease markers of HIV 1& 2, hepatitis B & C virus and RPR.
Absence of significant disease or clinically' significant abnormal laboratory values on laboratory evaluation, medical history and medical examination during the screening
A normal 12 lead ECG.
A normal chest X-ray (FA view)
Comprehension of the nature and purpose'of the study and compliance with the requirement of the entire protocol
No history or no evidence of hypersensitivity to rabeprazole substituted benzimidazoles or to any component of the formulation
No history of Anaphylaxis arid Angioedema
No history or presence of gastric malignancy
No history of significant systemic diseases
No history of psychiatric disorders
No history of addiction to any recreational drug or drug dependence
No donation of blood(one unit or 350 mL) within 90 days prior to study check-in
No participation in any clinical study within the last 90 days
No receipt of any prescription drugs or over-the-counter drugs (e.g.: Cold preparations, and antacid preparations' vitamins and natural products used for therapeutic benefits), within two weeks prior to study check-in
No history of dehydration from diarrhea, vomiting or any other reason within a period of 24.0 hours prior to study check-in
No family history of neurological disorders
Not consumed alcohol and xanthin containing food and beverages, (chocolates, tea,coffee or cola drinks) cigarettes and tobacco products for at least 48.0 hours prior to study check-in for each period.
Negative results for drugs of abuse (Benzodiazepines, Cocaines, Opioids, Amphetamines, Cannabinoids and Barbiturates) in urine during the day of study check-in of each period
Not consumed grapefruit(mosumbi/sweet lime) juice within the 48.0 hours prior to study check-in
Negative alcohol breath analysis during the study check-in of each period
Exclusion Criteria:
History of seizures
Received pharmacological agents known to significantly induce or inhibit drug metabolizing enzymes within 14 days of the start of the study
History of alcohol consumption for more than two units/day (1 unit=30 mL of spirit/or 1 pint of beer), or having consumed alcohol within 48.0 hours prior to check-in
High caffeine (more than 5 cups of coffee or tea/day) or tobacco (mote than 9 cigarettes/beedies/cigars per day) consumption
History of difficulty with donating blood or difficulty in accessibility of veins
An unusual or abnormal diet for whatever reason e.g. because of fasting due to religious reasons
Facility Information:
Facility Name
AXIS Clinicals Limited
City
Miyapur
State/Province
Hyderabad
ZIP/Postal Code
500 050
Country
India
12. IPD Sharing Statement
Learn more about this trial
Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fed Conditions
We'll reach out to this number within 24 hrs